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The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (TK) that—once activated upon
ligand binding—leads to receptor dimerization, recruitment of protein complexes, and activation of multiple
signaling cascades. The EGFR is frequently overexpressed or mutated in various cancers leading to aberrant
signaling and tumor growth. Hence, identification of interaction partners that bind to mutated EGFR can help
identify novel targets for drug discovery.
Here, we used a systematic approach to identify novel proteins that are involved in cancerous EGFR
signaling. Using a combination of high-content imaging and a mammalian membrane two-hybrid protein–
protein interaction method, we identified eight novel interaction partners of EGFR, of which half strongly
interacted with oncogenic, hyperactive EGFR variants. One of these, transforming acidic coiled-coil proteins
(TACC) 3, stabilizes EGFR on the cell surface, which results in an increase in downstream signaling via the
mitogen-activated protein kinase and AKT pathway. Depletion of TACC3 from cells using small hairpin RNA
(shRNA) knockdown or small-molecule targeting reduced mitogenic signaling in non-small cell lung cancer
cell lines, suggesting that targeting TACC3 has potential as a new therapeutic approach for non-small cell lung
cancer.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Background
Signal transduction by growth factor receptors is
essential for cells to maintain proliferation and differ-
entiation and requires tight control. Mutations in
signaling pathways frequently lead to the development
of cancer [1]. Signal transduction by growth factor
receptors is initiated by the binding of an external
ligand to a transmembrane receptor such as the
epidermal growth factor (EGF) receptor (EGFR) and
activation of downstreamsignaling cascades [2]. A key
regulator of EGFR signaling is growth factor receptor-Authors. Published by Elsevier Ltd. This
mmons.org/licenses/by/4.0/).bound protein 2 (Grb2), which is composed of an
internal Src homology (SH) 2 domain flanked by two
SH3 domains [3]. Grb2 binds to activated growth factor
receptors at phosphorylated tyrosine residues through
its SH2 domain, thus coupling receptor activation to
SOS-Ras-mitogen-activated protein kinase (MAPK)
signaling cascades. The modular composition of Grb2
suggests that it can dock to a variety of receptors and
transduce signals along multiple pathways.
EGFR is often found overexpressed or mutated in
cancer. These mutations can lead to constitutively
active EGFR that triggers downstream signalingis an open access article under the CC BY
J Mol Biol (2017) 429, 280–294
281Oncogenic EGFR Interaction Partnerscascades, leading to uncontrolled cell growth [4]. For
instance, several mutations found in lung cancer are
located in the tyrosine kinase (TK) domain of EGFR.
Some of these mutations, such as the L858R
substitution, render the receptor susceptible to small-
molecule inhibitors including the TK inhibitors (TKI)
erlotinib and gefitinib [5,6]. However, non-small cell
lung cancer (NSCLC) patients who show an initial
response to these drugs often develop resistance to
erlotinib treatment overtime by acquiring a secondary
T790M mutation [7]. Compounds such as the new
FDA-approved AZD9291 (Tagrisso) aim to overcome
secondary resistance mutations. However, the occur-
rence of tertiary mutations in these cases is a majorFig. 1 (legend onconcern. Hence, the identification of drug targets
downstream of the EGFR that preferably interact with
mutated EGFR receptors might overcome these
problems.
While the EGFR signaling pathway is reasonably
well understood, the interaction of specific signaling
components with mutated EGFR is not well studied
[8]. Multiple assays enable the identification of
EGFR interaction partners using “OMICS” ap-
proaches [9]. However, these methods are techni-
cally challenging and costly, and until recently,
genomic tools for a systematic identification of
interaction partners of mutant EGFRs have been
missing.next page).
282 Oncogenic EGFR Interaction PartnersIn order to systematically identify novel signaling
molecules in growth factor signaling, we used a
previously established microscopy-based green fluo-
rescent protein (GFP)-Grb2 translocation assay that
monitors the translocation of cytosolic GFP-tagged
Grb2 to subcellular compartmentsuponexpressionof a
cDNA library [10]. In a second step, to assess whether
the translocation inducers participate in EGFR signal-
ing, we tested proteins identified in the Grb2 transloca-
tion assay for their potential to bind to the EGFR using
the mammalian two-hybrid (MaMTH) approach [11],
which specifically allows for assaying interaction
patterns of integral membrane proteins such as
EGFR and allows for investigation of phosphorylation-
dependent changes in interaction patterns. We
found that 11 proteins bound to wild-type EGFR,
and 8 of those were further confirmed by co-
immunoprecipitation. Four of those eight further
bound strongly to oncogenic EGFR variants that are
predominantly found in NSCLC. We showed that one
of them, transforming acidic coiled-coil proteins
(TACC) 3, increases EGFR stability and promotes
downstream EGFR signaling. Finally, we showed
that targeting TACC3 in TKI-resistant NSCLC cells
partially overcomes this resistance.
Results
Identification of novel EGFR interaction partners
In order to identify novel proteins that participate in
growth factor receptor signaling, we combined a
previously established Grb2 translocation assay and
the recently developed MaMTH system [10–12]
(Fig. 1a). Given the central role of Grb2 in growthFig. 1. Identification of novel EGFR interaction partners. (a
GFP-tagged Grb2 translocation to activated growth factor rece
used to identify novel interaction partners of the EGFR. In the G
signaling will lead to the recruitment of Grb2 to the cell surfac
translocation of GFP from the cytoplasm to punctate structures
proteins with respect to interaction with the EGFR. Briefly, an in
TF (GAL4-NFκB). The 19 prey proteins are tagged with Nub. Bo
stable luciferase reporter HEK293T cell line. If the bait and p
proteolytic cleavage by deubiquitinating enzymes (DUBs) an
nucleus, resulting in reporter gene activation. GFP-Grb2 trans
validated by co-immunoprecipitation. (b) HeLa cells were co
proteins, and the next day, fluorescence microscopy was perfo
platform. Scale bar represents 20 μm. Arrows indicate area
localization of GFP-Grb2 translocation hits. (d) GO annotation
HEK293T-5xGAL4UAS luciferase reporter cells were infecte
control, and after double stable reporter/prey cell line generatio
transfection, cells were lysed and luciferase activity was me
compared to an averaged panel of negative control preys. D
biological replicates). Asterisks show p-values: ⁎⁎⁎p b 0.001, ⁎⁎
with EGFR-WT-GFP and 11 FLAG-tagged EGFR interaction p
day, cells were stimulated with EGF for 10 min and lysed. E
anti-FLAG beads, and the association of EGFR was examin
control for equal EGFR-WT expression. Asterisks indicate th
respective interaction partner.factor signaling, we designed an assay that allows the
monitoring of the activation status of a cell, based on
the translocation of GFP-tagged Grb2 to subcellular
sites such as the plasma membrane or endosomes
[10,13]. We identified 19 proteins that induced the
translocation of GFP-Grb2 from the cytosol to distinct
spots upon co-transfection with GFP-Grb2 in HeLa
cells (Fig. 1b). Most of the 19 proteins led toGFP-Grb2
translocation to punctate structures of variable size
and number, suggesting different modes of action of
the 19 translocation hits. Lzts2, TACC3, and Shkbp1
led to clusters of cytosolic GFP-Grb2, whereas Dok3,
Amph, Diaph1, and Cnk2 resulted in multiple and
distinct GFP-Grb2 spots. All other genes resulted in
smaller punctate structures (Fig. 1b and Table 1). A
punctate pattern of Grb2 localization may be indicative
of Grb2 recruitment by cell surface receptors and
subsequent internalization, through either direct bind-
ing or indirect activation of signaling molecules. Gene
ontology (GO) annotation for localization and function
for the GFP-Grb2 translocation hits showed that the
majority of the 19 hits have a GO function involved in
signaling pathways (43.5%) and cytoplasmic GO
localization (37.5%; Table 1 and Fig. 1c and d).
Someof the hitsmay function downstreamofGrb2, but
we hypothesized that some may also be linked to cell
surface receptor activation. One candidate growth
factor receptor that we were particularly interested in is
EGFR. Therefore, in order to test whether any of these
proteins are putative EGFRbinding partners, wemade
use of the recently established MaMTH system [11],
which allows for the detection of phosphorylation-
dependent interactions of membrane proteins such as
EGFR (Fig. 1a). Briefly, a membrane bait protein is
tagged with the C-terminal half of ubiquitin (Cub) and a
transcription factor (TF), and the cytosolic or) A combination of an image-based assay that monitors
ptors and a cell-based mammalian two-hybrid assay was
FP-Grb2 translocation assay, an increase in growth factor
e and subsequent internalization, which is reflected by a
. In a second step, MaMTH was used to monitor the same
tegral membrane protein (EGFR) is tagged with Cub and a
th bait and prey are co-transfected or co-transduced into a
rey interact, ubiquitin reconstitution occurs, leading to the
d the subsequent release of the TF. The TF enters the
location hits and MaMTH-positive interactors were further
-transfected with GFP-Grb2 and indicated FLAG-tagged
rmed on the PerkinElmer Opera LX high-content screening
s of GFP-Grb2 recruitment. (c) GO annotation for the
for the function of GFP-Grb2 translocation hits. (e) Stable
d with 19 indicated lentiviral preys and Grb2 as positive
n, cells were transfected with EGFR-WT. Then, 24 h after
asured. Luciferase activity of each prey is displayed and
ata are presented as means ± standard deviation (n = 3
p b 0.01, ⁎p b 0.05. ( f) HEK293T cells were co-transfected
artners. FLAG-Grb2 was used as positive control. The next
GFR interaction partners were immunoprecipitated using
ed by GFP immunoblotting. Input samples were used to
e predicted molecular weight for full-length protein of the
Table 1. GO localization and GO function of 19 GFP-Grb2 localization hits
UniProt GFP-Grb2 localization GO localization GO function
AMPH P49418 Spots in cytoplasm Cytoplasm, cytoskeleton, trans-Golgi Regulation of GTPase activity
APBB1IP Q7Z5R6 Spots in cytoplasm, nucleus Cytosplasm, cytoskeleton,
plasma membrane
Signal transduction
BCL6 P41182 Small spots in nucleus Nucleus Regulation of GTPase activity,
signaling, transcription
CNK2 Q8WXI2 Spots in cytoplasm Cytoplasm, Golgi apparatus, membrane Regulation of signal transduction
DDX17 Q92841 Single spot in cytoplasm Nucleus Regulation of transcription, RNA helicase
DIAPH1 O60610 Spots in cytoplasm Cytoplasm, cytoskeleton, plasmamembrane Actin cytoskeleton organization
DOK3 Q7L591 Spots in cytoplasm Cytoplasm, plasma membrane Ras protein signal transduction
ENAH Q8N8S7 Few spots in nucleus Cytoplasm, cytoskeleton, focal adhesion Actin cytoskeleton organization
LZTS2 Q9BRK4 Clustered perinuclear spots Cytoplasm, centrosome, cytoskeleton Cell division, Wnt signaling pathway
MBIP Q9NS73 Few spots in cytoplasm Cytoplasm, nucleus Chromatin organization
PHF8 Q9UPP1 Few spots in cytoplasm Nucleus Mitotic cell cycle, chromatin organization
PRAM1 Q96QH2 Few spots in nucleus NA Integrin-mediated signaling pathway
RIMS2 Q9UQ26 Single spot in cytoplasm Plasma membrane cAMP-mediated signaling, regulation
of exocytosis
SHKBP1 Q8TBC3 Clustered spots in cytoplasm NA Positive regulation of EGFR signaling
SKAP2 O75563 Few spots in cytoplasm Cytoplasm, plasma membrane Signal transduction
ST5 P78524 Few spots in cytoplasm NA Regulation of GTPase activity
TACC3 Q9Y6A5 Large spots in cytoplasm Cytoplasm, microtubule, cytoskeleton Microtubule cytoskeleton organization
TUFT1 Q9NNX1 Spots in cytoplasm, nucleus Cytoplasm, extracellular region Intracellular signal transduction
Usp33 Q8TEY7 Few spots in cytoplasm Cytoplasm, cytoskeleton, Golgi Protein deubiquitination
NA – not annotated
283Oncogenic EGFR Interaction Partnersmembrane-bound prey is coupled to the N-terminal
half of ubiquitin (Nub). Upon bait and prey interaction,
the split-halves form pseudo-ubiquitin, which is recog-
nized by cytosolic deubiqitinating enzymes, resulting in
TF cleavage and reporter gene expression (Fig. 1a).
For the MaMTH interaction screen, 5xGAL4UAS-
luciferase reporter cells were infected with lentiviral
vectors expressing thepreys at amultiplicity of infection
(MOI) of 0.4, selected in puromycin for 3 days, and
transfected with EGFR-wildtype (EGFR-WT). Then,
24 h after transfection, cell counts were assayed and
luciferase activity wasmeasured. Our interaction score
cutoff is based on the difference in luciferase activity
over averaged negative controls (see Materials and
Methods).Out of 19preys,we identified11proteins that
interacted with EGFR-WT (Fig. 1e).
To further validate the 11 novel EGFR interactors, we
performed co-immunoprecipitation studies. Briefly,
HEK293T cells were co-transfected with FLAG-
tagged interactors and GFP-tagged EGFR-WT, and
24 h after transfection, cells were lysed and lysates
were subjected to immunoprecipitation with FLAG-
antibodyandprobed for associationwithEGFRbyGFP
immunoblotting. Moreover, 8 of 11 proteins (TACC3,
Skap2, Dok3, Cnk2, Amph, Lzts2, Usp33, and Mbip)
were confirmed to bind to EGFR-WT (Fig. 1f).
Identification of novel oncogenic EGFR interaction
partners
In addition to assessing the overall binding to
EGFR-WT, we also tested the binding pattern of the
11 interactors to 3 mutant EGFR variants that are
predominantly found in NSCLC: EGFR-L858R,EGFR-exon19 deletion (EGFR-ex19del), and
EGFR-T790M/L858R. These mutant EGFR variants
are constitutively active and lead to increased
downstream signaling [4,7]. L858R and ex19del
render the receptor more susceptible to TKIs such as
erlotinib or gefinitib, whereas the secondary T790M
mutation confers resistance to TKIs [6]. We used this
set of mutant EGFRs to characterize which of our
novel EGFR interaction partners bind preferentially
to oncogenic EGFRs using the MaMTH system.
The majority of novel interaction partners (6 out of
11, 54.5%; Diaph1, Dok3, Rim2, Skap2, TACC3,
and Usp33) showed preferential binding to all three
oncogenic variants compared to EGFR-WT, sug-
gesting an increased recruitment of phosphorylation-
dependent interactors. In comparison, only two
preys (18.2%;Amph and Lzts2) bound preferentially
to EGFR-WT and three (27.3%) showed a similar
binding pattern for wild-type and mutant receptors
(Cnk2, Ddx17, and Mbip; Fig. 2a).
We next sought to narrow down EGFR interactors
that are most likely to be involved in EGFR signaling
pathways by computational analysis and database
mining. We identified seven proteins (Amph, Dok3,
Ddx17, Mbip, Rim2, Skap2, TACC3, and Usp33) that
are predicted to be EGFR interaction partners and/or
share interaction partners within the EGFR pathway,
and three of these (Amph, Rim2, and TACC3) show
increased expression levels in lung cancer (Fig. 2b
and Supplementary Table 1). Since several proteins
involved in EGFR signaling require binding to
phosphorylation sites within the cytoplasmic tail of
the receptor [2], we explored whether the identified
EGFR interaction partners contain any obvious
Fig. 2. Identificationof novel oncogenicEGFR interactionpartners. (a) StableHEK293T-5xGAL4UAS luciferase reporter cells
were infected with 19 indicated lentiviral preys, and after double stable reporter/prey cell line generation, cells were then
transfected with EGFR-WT, EGFR-L858R, EGFR-ex19del, or EGFR-T790M/L858R. Then, 24 h after transfection, cells were
lysed and luciferase activity was measured. Luciferase activity is displayed as the ratio above a panel of negative control preys.
Strength of interaction between each prey and EGFR-L858R, EGFR-ex19del, or EGFR-T790M/L858R is compared to the
corresponding EGFR-WT interaction pattern. Data are presented as means ± standard deviation (n = 3 biological replicates).
Asterisks show p-values: ⁎⁎⁎p b 0.001, ⁎⁎p b 0.01, ⁎p b 0.05. Pie chart indicates how many preys bind more strongly to EGFR-
WTand the oncogenic EGFRvariants or showa similar binding pattern. (b) The dot blot displays differential strength of binding to
EGFR-WT compared to EGFR-L858R (left), EGFR-ex19del (middle), and EGFR-T790M/L858R (right); preys close to the y-axis
are those that interactedmorestronglywithEGFR-L858R,EGFR-ex19del, orEGFR-T790M/L858R,andpreys close to thex-axis
showed stronger interaction with EGFR-WT (for MaMTH interaction scores, see Fig. 2a). Preys along the diagonal dotted line
interacted similarly with WT and oncogenic mutants. Blue node fill color indicates if preys are predicted EGFR interactors. Node
outline colors indicate if preys are found in prognostic lung cancer signatures, and node shape indicates if preys have been
reported to be up- or down-regulated in lung cancer. Letters within the nodes indicate the presence of SH2, PTBdomain, or other
signaling domains.
284 Oncogenic EGFR Interaction PartnersEGFR bindingmotif such as SH2 or PTB sequences.
Five proteins (Amph, Diaph1, Dok3, Rim2, and
Skap2) have known signaling domains (Fig. 2b and
Supplementary Table 1), but none of the 19 hits
harbor SH2 or PTB sequences, (Fig. 2b and
Supplementary Table 1).
We decided to investigate in detail the role of TACC3
inEGFRsignaling, as it has previously not beendirectly
linked to EGFR signaling, led to pronounced spot
formation of GFP-Grb2 recruitment, and showed the
strongest interaction with oncogenic EGFRs (Fig. 2a
and b). Furthermore, TACC3 has previously beenshown to be up-regulated in lung cancer and, based on
our computational analysis, is a prognostic lung cancer
marker (Fig. 2b and Supplementary Table 1).
First, in order to exclude that TACC3 leads to GFP
spot formation of any GFP-tagged protein, not only
GFP-Grb2, we co-expressed FLAG-TACC3 with
GFP-Grb2, GFP-only, and an unrelated protein,
GFP-Fabp5.Whereas TACC3 induced spot formation
when co-expressed with GFP-Grb2, it did not alter
cytosolic localization of both GFP-only and
GFP-Fabp5, indicating that the effect of TACC3 on
GFP-Grb2 translocation is specific (Fig. 3a). Next, in
Fig. 3. TACC3 is a novel EGFR interaction partner. (a) HeLa cells were either transfected with GFP-Grb2, GFP-only, or
GFP-Fabp5 or co-transfected with FLAG-TACC3 and GFP-Grb2, GFP-only, or GFP-Fabp5. The next day, fluorescence
microscopy was performed. Scale bar represents 20 μm. (b) HEK293T cells were co-transfected with EGFR-WT-bait
(Cub-GAL4-NFκB-V5), Diaph1-bait, and Nub-TACC3 prey. The next day, cells were lysed and TACC3-prey expression
was assessed using FLAG-antibody. Bait expression and cleaved off TF were assessed by V5 immunoblotting.
(c) HEK293T cells were co-transfected with GFP-tagged EGFR-WT, EGFR-L858R, EGFR-ex19del, or EGFR-T790M/
L858R and FLAG-tagged TACC3. Then, 8 h after transfection, media was changed to starvation media for additional 16 h,
and cells were then lysed. TACC3 was immunoprecipitated using anti-FLAG beads, and the association of EGFR was
examined by GFP immunoblotting. Input samples were used to control for equal EGFR-WT expression. (d) HEK293T cells
were co-transfected with EGFR-WT, EGFR-L858R, EGFR-ex19del, or EGFR-T790M/L858R-baits and TACC3-prey.
Then, 6 h after transfection, cells were starved overnight, erlotinib was added (1 μM) for 3 h, and cells were stimulated with
EGF (100 ng/μl) for 10 min. Cells were lysed and luciferase assays performed. Relative luciferase activities compared to
EGFR-WT are shown. Data are presented as means ± standard deviation (n = 3 biological replicates). Asterisks show
p-values: ⁎⁎⁎p b 0.001.
285Oncogenic EGFR Interaction Partnersorder to exclude that the TACC3-prey is unspecific
and binds to any bait protein in our interaction assay,
we performed aMaMTHassay testing the interactions
between TACC3-prey and EGFR-bait, and an unre-
lated bait, Diaph1. Whereas TF cleavage occurred
when co-expressing EGFR-bait and TACC3-prey in
HeLa cells, no cleavage could be detected in HeLa
cells co-expressing Diaph1-bait and TACC3-prey,
suggesting the TACC3–EGFR interaction is specific.
(Fig. 3b). We next tested whether TACC3 binds to
oncogenic EGFR by co-immunoprecipitation. Indeed,
we see an increased binding affinity of TACC3 to
oncogenic EGFR variants even in the absence of
growth factor or serum compared to EGFR-WT (Fig.
3c). Since oncogenic EGFR variants—unlikeEGFR-WT—are phosphorylated even in starvation
conditions, this suggests that TACC3 mainly binds to
phosphorylated EGFR.
To investigate whether TACC3 has higher affinity
for phosphorylated EGFR, we then performed
MaMTH interaction assays and tested the binding
of TACC3 to EGFR-WT and oncogenic EGFR
variants upon erlotinib treatment in the presence of
growth factors. Both L858R and exo19del mutations
render EGFR more susceptible to erlotinib, which
leads to rapid dephosphorylation of the mutated
receptor. Briefly, stable HEK293T reporter cells were
transfected with EGFR-baits and TACC3-prey,
starved overnight, treated with erlotinib for 3 h, and
then stimulated with epidermal growth factor (EGF)
286 Oncogenic EGFR Interaction Partnersfor 10 min. We could observe that while erlotinib
treatment readily abolished the binding of TACC3 to
EGFR-L858R and EGFR-ex19del, it did not affect
the binding of TACC3 to EGFR-WT and
EGFR-T790M/L858R (Fig. 3d). Thus, TACC3 pref-
erentially binds to oncogenic EGFR variants in an
erlotinib-sensitive and phosphorylation-dependent
manner.
TACC3 binds to oncogenic EGFRs and stabilizes
EGFR at the cell surface
Based on our results that TACC3 binds to EGFR
and preferentially to oncogenic EGFR variants, we
next tested whether TACC3 can modulate EGFR-
mediated signaling, either directly at the receptor
level or downstream. One hypothesis was that
TACC3 might stabilize EGFR on the cell surface or
increase EGFR levels in general, thus keeping the
receptor in a signaling-competent state for a longer
period of time and/or that TACC3 modulates EGFR
endocytosis.
We first tested the effect on overall EGFR stability
upon knockdown and overexpression of TACC3. We
treated HeLa cells harboring either overexpressed or
depleted TACC3 with cycloheximide to block protein
synthesis and monitored EGFR degradation. After
cycloheximide treatment, EGF-induced EGFR deg-
radation was accelerated significantly in TACC3
knockdown cells and in cells treated with a small-
molecule targeting TACC3, KHS101 [14,15]. Inter-
estingly, treatment with KHS101 resulted in reduced
expression of TACC3 similar to shRNA-mediated
knockdown, an effect that has not been reported
previously. In contrast, overexpression of TACC3 led
to reduced EGFR degradation compared to control
cells (Fig. 4a). EGFR degradation in TACC3
knockdown cells or KHS101-treated cells started
earlier when compared to mock transfected cells and
was complete within 2 h. We next tested whether
TACC3 directly influences cell surface EGFR levels.
We transfected EGFR-GFP in HeLa cells stably
expressing FLAG-TACC3, starved them overnight,
and treated them with Alexa-EGF555 for 60 min.
Whereas EGFR-GFP and Alexa-EGF colocalized
in the cytoplasm in control cells (Fig. 4b), EGFR-GFP
was mainly found at the cell surface of TACC3-
overexpressing cells, with similar effects seen for
EGFR-L858R (Fig. 4c); EGFR was not detectable at
the plasma membrane in control (Fig. 4b and c) and
TACC3 knockdown cells (Fig. 4c). Furthermore, we
performed cell surface biotinylation assays, which
confirmed increased cell surface EGFR expression in
TACC3-overexpressing cells (Fig. 4d). In summary,
we conclude that TACC3 increasesEGFRstability and
levels at the cell surface. However, we did not see a
complete block of internalization, as evidenced by the
uptake of Alexa-EGF in the cells in the presence or
absence of TACC3.TACC3 promotes mitogenic signaling
We next tested whether TACC3 expression results
in enhanced activation of mitogenic signaling path-
ways. First, as a readout of MAPK signaling, we
used the serum response element (SRE)-luciferase
luciferase reporter that is activated upon enhanced
MAPK signaling via the serum response factor [16].
Briefly, HEK293T cells were co-transfected with
SRE-luciferase, and luciferase activity was mea-
sured upon overexpression of TACC3 or
shRNA-mediated knockdown in the presence of
serum. Constitutively active K-Ras V12 was used as
a positive control, and we observed a strong
increase in luciferase activity upon transfection
(Supplementary Fig. 1a). Upon co-transfection of
TACC3 with SRE-luciferase in HEK293T cells, we
observed a fivefold increase of SRE-luciferase
activity upon TACC3 overexpression compared to
control vector (Fig. 5a). A similar increase was also
observed in starvation conditions (Supplementary
Fig. 1b). Furthermore, shRNA-mediated knockdown of
TACC3 in HeLa cells led to decreased SRE luciferase
activity (Fig. 5b), indicating that TACC3 enhances
mi togen ic s igna l ing . Nex t , we assayed
EGFR-dependent MAPK activation throughmeasuring
the phosphorylation of extracellular signal-regulated
kinase (ERK)1/2 in the presence or absence of EGF.
Stimulation of HeLa cells with EGF resulted in an
increase in phospho-ERK1/2 as expected, which is lost
upon knockdown of TACC3 (Fig. 5c) or treatment of
cells with KHS101 (Fig. 5d). Overall, these results
suggest that TACC3 promotes MAPK activity down-
stream of EGFR signaling.
Next, we explored whether TACC3 also enhances
signaling more proximal to the EGFR. Knockdown of
TACC3 in HeLa cells or treatment with KHS101
resulted in a reduction of phosphorylated EGFR
levels and of EGFR levels in general, when
compared to mock transfected cells (Fig. 5e). As
shown in Fig. 5e, knockdown of TACC3 or KHS101
treatment resulted in reduced phospho-ERK1/2
levels and reduced phospho-AKT levels. We also
observed similar effects on phospho-EGFR levels in
HEK293T cells (Supplementary Fig. 2). Based on
our results that a decrease in downstream signaling
such as phospho-ERK1/2 and phospho-AKT corre-
lated with decreased EGFR levels (Fig. 5e), we
suggest that TACC3 stabilizes EGFR at the cell
surface and increases its overall expression and
stability, thus increasing signaling pathways down-
stream of EGFR.
Inhibition of TACC3 partially restores TKI
sensitivity in TKI-resistant NSCLC cells
Next, we sought to test the influence of TACC3 on
EGFR signaling in NSCLC cells and tested whether
the targeting of TACC3 has an effect on NSCLC
287Oncogenic EGFR Interaction Partnerscells that are resistant to TKI treatment. TACC3 has
been previously shown to be overexpressed in various
cancers, including lung cancer [17,18]. Moreover,
Kaplan–Meier (KM) survival analysis† [19] showed
that high expression of TACC3 is significantly associ-
atedwith poor survival in lung cancer patients (Fig. 6a).
First, we examined TACC3 expression levels in two
NSCLC cell lines that harbor hyperactive EGFR,
HCC827 (ex19del) and H1975 (T790M/L858R). We
show that both cell lines have increased TACC3Fig. 4 (legend onexpression when compared to H226-NSCLC that
expresses EGFR-WT (Fig. 6b).
We next tested whether targeting TACC3 has an
influence on TKI sensitivity in NSCLC cells. As
expected, we show that HCC827 (ex19del)-NSCLC
cells are susceptible to the TKI erlotinib, as indicated
by reduced phospho-ERK1/2 signaling upon erlotinib
treatment, whereas H1975 cells harboring the T790M
mutation are resistant to erlotinib (Fig. 6c). Interestingly,
knockdown of TACC3 partly resensitized H1975 cellsnext page).
288 Oncogenic EGFR Interaction Partnersto erlotinib, as observed through a reduction in
phospho-ERK1/2 levels (Fig. 6d) and decreased cell
viability upon erlotinib addition (Fig. 6e). Similarly,
treatment with the TACC3 inhibitor compoundKHS101
partially resensitized H1975 cells to erlotinib (Fig. 6d
and e), thus indicating that small-molecule targeting of
TACC3 is a viable strategy to restore TKI sensitivity in
resistant cell lines. We then tested whether the
reduction in phospho-ERK1/2 is correlated with a
reduction of EGFR in H1975 cells, as observed in
HeLa cells (Figs. 4a and 5e). Indeed, combined
targeting of TACC3 and erlotinib treatment reduced
both EGFR levels and, concomitantly, phospho-EGFR
levels in H1975 cells (Fig. 6f). In summary, this
suggests that targeting TACC3 in NSCLC can lower
overall EGFR and phospho-levels and could thus
render cells more responsive to TKI treatment.Discussion
Abnormal EGFR signaling is the central mechanism
for various cancers, often arising from mutated EGFR
that triggers downstream signaling cascades, resulting
in aberrant cellular growth and ultimately tumor
formation [20]. EGFR signaling is complex and can
diverge from one input signal, like ligand–receptor
interaction, into multiple output signals, which aggra-
vate efficient EGFR-targeted strategies. Plus, frequent
resistance mutations and up-regulation of other signal-
ing pathways pose a major hurdle to the development
of clinical therapies [5,9]. Hence, targeting proteins that
associatewithEGFRcan increase therapeutic efficacy.
Here, we identified novel EGFR interaction partners
that specifically bind to oncogenic EGFR.
First, we used a high-content screening assay that
monitors the distribution of GFP-Grb2 upon overex-
pression of a cDNA library [10]. This assay is amenable
to high-throughput screening, is very cost-effective, and
can relay information about localized signaling
complexes in live cell or as a fixed end-point assay
[13]. The Grb2 translocation assay does not discrim-Fig. 4. TACC3 stabilizes EGFR at the cell surface. (a)
constructs. After 2 days, cells were starved overnight, pre-trea
with cycloheximide for 1 h, and stimulated with EGF (100 ng/μ
then lysed and subjected to Western blot analysis using EG
(b) HeLa cells stably expressing FLAG-TACC3 and control HeL
with EGFR-GFP. Then, 2 days after transfection, cells were s
60 min, and fixed;fluorescence microscopy was performed. Sc
two independent experiments, and overall cell surface GFP
coverslips and transfected with EGFR-GFP or EGFR-L858
transfection, cells were starved overnight, then stimulated
fluorescence microscopy was performed. Scale bar represents
TACC3 or empty FLAG-vector control. Then, 2 days after tran
EGF (100 ng/μl) for 60 min. Cell surface proteins were biotiny
beads. Cell surface EGFR levels were assessed by Western
antibody and transferrin receptor antibody. EGFR and TACC3
densities of the EGFR bands were quantified using ImageJ soft
presented as means ± standard deviation. Asterisks show p-vinate between specific growth factor receptors unless
a specific ligand is used. Thus, the assay can
conveniently monitor the general activation state of a
cell and systematically identify cellular factors that
enhance general Grb2-mediated signaling. To further
focus on factors that enhance EGFR signaling via
Grb2, we used the recently developed protein–protein
interaction detection techniqueMaMTH [11].Wewere
able to validate some GFP-Grb2 translocation hits as
binding partners for the EGFR and examined the
potential for interaction with oncogenic variants of the
EGFR. This pipeline can be applied to other signaling
receptors and pathways andwill open newavenues to
study other signaling-related protein-protein interac-
tion (PPI) maps.
Using this approach, we identified and validated
eight novel EGFR interaction partners, of which four
bound more strongly to oncogenic EGFR. We
showed that TACC3 harbors oncogenic properties,
through stabilizing cell surface EGFR levels, and
further showed that TACC3 can partially restore TKI
sensitivity in NSCLC cells that are TKI resistant.
TACC3 is a member of transforming acidic coiled-
coil proteins (TACCs), which are important players of
centrosome- and microtubule-associated functions
[17,21]. TACC3 stabilizes and organizes the mitotic
spindle to allow proper chromosome segregation [22].
It has been shown that Aurora A-mediated TACC3
phosphorylation is essential for its localization to
mitotic spindles and centrosomes [23,24].
Growing evidence suggests that TACC3 is found
overexpressed in many human cancers, including
ovarian cancer, breast cancer, squamous cell carci-
noma, and lung cancer [17,18,25,26]. Survival analy-
sis using lung cancer patients (n = 1926) in KMPlotter
shows significant association of high expression of
TACC3 with poor survival (HR = 1.8; p-value b1e−16)
[19]. Multiple roles for TACC3 in cancer progression
havebeen described: high levels of TACC3can lead to
accumulation of DNA double-strand breaks and
disrupt normal DNA damage pathways and proper
chromosome segregation [27]. TACC3 has also beenHeLa cells were seeded and transfected with indicated
ted with KHS101 (5 μM) for 3 h (where indicated), treated
l) for indicated times to assess EGFR stability. Cells were
FR, phospho-ERK1/2, ERK1/2, and TACC3 antibodies.
a cells were seeded onto glass coverslips and transfected
tarved overnight, then stimulated with EGF (100 ng/μl) for
ale bar represents 10 μm. Then, 30 cells were counted in
was assessed. (c) HeLa cells were seeded onto glass
R-GFP and FLAG-tagged TACC3. Then, 2 days after
with Alexa-EGF555 (100 ng/μl) for 60 min, and fixed;
10 μm. (d) HeLa cells were transfected with FLAG-tagged
sfection, cells were starved overnight and stimulated with
lated and immunoprecipitated using streptavidin-coupled
blot analysis of immunoprecipitated samples using EGFR
expression levels of input samples were assessed. The
ware and normalized against transferrin receptor. Data are
alues: ⁎p b 0.05.
Fig. 5. TACC3 promotes mitogenic signaling. (a) HEK293T cells were co-transfected with SRE-luciferase reporter and
empty vector control (E.V.) or FLAG-tagged TACC3. Then, 3 days after transfection, cells were lysed and luciferase
activity was measured. Values were normalized to the empty control vector, and changes in activity are displayed as fold
values. Data are presented as means ± standard deviation (n = 3 biological replicates). Asterisks show p-values:
⁎⁎⁎p b 0.001. (b) HEK293T cells were co-transfected with SRE-luciferase reporter and empty vector control (E.V.) or two
shTACC3-lentiviral constructs. Then, 3 days after transfection, cells were lysed and luciferase activity was measured.
Values were normalized to the empty control vector, and changes in activity are displayed as fold values. Data are
presented as means ± standard deviation (n = 3 biological replicates). Asterisks show p-values: ⁎⁎⁎p b 0.001. (c) HeLa
cells were infected with indicated lentivirus (shGFP control or shTACC3) and selected for 48 h to obtain stable cells. Cells
were then seeded, starved overnight, and stimulated with EGF (100 ng/μl) for 10 min. Cells were lysed and protein levels
were assessed by Western blot using phospho-ERK1/2 and ERK1/2 antibodies and TACC3-antibody to control for
knockdown efficiency. (d) HeLa cells were starved overnight, treated with KHS101 (5 μM) for 3 h or left untreated and then
stimulated with EGF (100 ng/μl) for 10 min. Cells were lysed and protein levels were assessed by Western blot using
phospho-ERK1/2, total ERK1/2 antibodies and TACC3-antibody. (e) HeLa cells were infected with indicated lentivirus
(shGFP control, shTACC3) and selected for at least 48 h to obtain stable cells. Cells were then seeded, starved overnight,
treated with KHS101 where indicated, and stimulated with EGF (100 ng/μl) for 10 min. Cells were lysed and protein levels
were assessed by Western blot using phospho-EGFR, phospho-ERK1/2, phospho-AKT, EGFR, ERK1/2, AKT, and
TACC3 antibodies.
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Fig. 6. Inhibition of TACC3 partially restores TKI sensitivity in TKI-resistant NSCLC cells. (a) KM plot for the overall
survival for 1926 lung cancer patients shows correlation of high TACC3 expression with poor patient survival [20].
(b) TACC3 protein levels were assessed by Western blot using cell lysates of H226-EGFR-WT, HCC827-EGFR-ex19del,
and H1975-EGFR-T790M/L858R NSCLC cells and using TACC3 antibody and ERK1/2 control antibody. HCC827 and
H1975 cell lysates were loaded in duplicates. (c) NSCLC cell lines HCC827-EGFR-ex19del and H1975-EGFR-T790M/
L858R were seeded and starved overnight. The next day, cells were either treated with erlotinib (1 μM) for 3 h or left
untreated and then stimulated with EGF (100 ng/μl) for 10 min. Cells were lysed andWestern blot analysis was performed
using phospho-ERK1/2, TACC3, and ERK1/2 antibodies. (d) NSCLC cell lines H1975-EGFR-T790M/L858R were infected
with indicated lentivirus (shGFP control or shTACC3) and selected for 48 h. Cells were then seeded and starved overnight.
The next day, cells were either treated with erlotinib (1 μM) and erlotinib plus KHS101 (5 μM) for 3 h or left untreated and
then stimulated with EGF (100 ng/μl) for 10 min. Cell were lysed and Western blot analysis was performed using
phospho-ERK1/2, TACC3, and ERK1/2 antibodies. (e) H1975-EGFR-T790M/L858R cells were stably infected with
indicated virus (shGFP control or shTACC3), seeded after 48 h of selection, and starved overnight. The next day, cells
were treated with indicated concentrations of erlotinib or erlotinib plus KHS101 overnight, and cell viability was assessed.
Values are normalized to samples without erlotinib addition. Data are presented as means ± standard deviation (n = 3
biological replicates). Asterisks show p-values: **P b 0.01, *P b 0.05. (f) H1975-EGFR-T790M/L858R were stably
infected with indicated lentivirus (shGFP-control or shTACC3) and selected for 48 h. Cells were then seeded and starved
overnight. The next day, cells were either treated with erlotinib (1 μM) and erlotinib plus KHS101 (5 μM) for 3 h or left
untreated and then stimulated with EGF (100 ng/μl) for 10 min. Cell were lysed and Western blot analysis was performed
using phospho-EGFR, EGFR, and ERK1/2 antibodies.
290 Oncogenic EGFR Interaction Partnersfound as a gene fusion product with the cytoplasmic
domain of the fibroblast growth factor receptor (FGFR)
in glioblastoma multiforme and lung cancer [28,29]. It
has been previously shown that TACC3 is involved in
cervical cancer progression and can induce epithelial–
mesenchymal transition by the activation of PI3K/Akt
and ERK1/2 signal transduction pathways [30]. Fur-
thermore, it has been shown that EGF promoted
TACC3 expression in an EGFR-dependent manner,supporting a link between EGFR signaling pathways
and TACC3 [31]. A recent interesting study revealed
that FGFR-TACC3 fusion protein can promote the
resistance of EGFR-dependent cancer cell lines
to EGFR/ErbB3 blockage via activation of ERK
signaling. The authors showed that FGFR-TACC3
protein led to the resistance of H1975-T790M/L858R
NSCLC cells to the TKI AZD9291. This study further
corroborates a direct link between TACC3 and
291Oncogenic EGFR Interaction PartnersEGFR signaling [32]. Our study identified TACC3 as
a novel EGFR interaction partner with multiple
oncogenic properties and provides a first indication
that TACC3 directly regulates EGFR signaling.
TACC3 interacts preferentially with oncogenic
EGFR in a phosphorylation-dependent way and
promotes MAPK signaling pathways, which correlate
with an increase in cell surface EGFR levels in
TACC3-overexpressing cells. These results suggest
that this interaction involves direct or indirect binding to
phosphorylated tyrosine residues in the EGFR. How-
ever, common phospho-tyrosine binding domains are
absent in TACC3. Another possibility is that interaction
with the EGFR is indirect, involving the Grb2 or Shc1
adapter proteins. To date, we did not find any obvious
interaction motif in TACC3 that can mediate such
binding, and the molecular detail of this interaction
requires further investigation. Our results suggest that
TACC3 promotes overall EGFR levels and EGFR
stability at the cell surface, thus increasing downstream
signaling pathways that are conferred by EGFR.
We showed that targeting TACC3 through knock-
down or treatment with TACC3 inhibitor KHS101 in
NSCLCcells that are resistant toTKI treatment resulted
in partial resensitizing of TKI-resistant NSCLC cells to
the TKI erlotinib.
In summary, our study identified various, novel
oncogenic EGFR interactors, and one of them,
TACC3, is a potential drug target for NSCLC and
could be targeted concomitantly with EGFR in order




Gateway-compatible entry clones: Entry clones
were obtained by the human ORFeome library v5.1
or PCR amplified from Mammalian Gene Collection
clones to create entry clones in pDONR223 using
Gateway BP cloning technology (Invitrogen) accord-
ing to the manufacturer's protocol. Entry clones were
sequence verified. Expression vectors: For MaMTH
interaction studies, bait and prey expression vectors
from Ref. [11] (lentiviral and mammalian expression
vectors) were used. All vectors used in this study are
listed in Supplementary Table 2. A list of primers can
be found in Supplementary Table 3.
Lentivirus generation and stable cell line
generation
Lentiviral reporter or prey plasmids were co-
transfected with psPAX2 and pMD2 into HEK293T
cells using X-tremeGene9 transfection reagent
(Roche) and Optimem-serum-reduced media (Gibco).
Then, 18 h after transfection,mediawere removed andreplacedbyviral harvestingmedia [Dulbecco'smodified
Eagle's medium (DMEM) + 1.1 g/100mL bovine serum
albumin (BSA)]. The first viral harvestwasperformed24
h later, and high-BSA harvesting media were added to
the cells. Again, after 24 h, the second harvest was
done and combinedwith the first harvest, and viruswas
stored at −80 °C. Lentiviral work was carried out in
accordance with all Biosafety requirements.
For stable cell line generation, target cells were
infected at aMOI between0.3 and0.5. Then, 24 hafter
infection, cells were selected with puromycin (2 μg/ml
for HEK293T and HeLa, 1,5 μg/ml for HCC827 and
H1975) for 48 h and expanded or frozen down for
further assays.
Cell culture
HEK293T and HeLa cells were cultured in DMEM
with 10% fetal bovine serum and 1% antibiotics
(penicillin/streptomycin). Starvation media consisted
of DMEM with 1% fetal bovine serum and 1%
antibiotics. Lung cancer cell lines H226, HCC827,
and H1975 were maintained in RPMI-1640 supple-
mented with 10% fetal bovine serum and antibiotics.
Starvation conditions were performed in DMEM or
RPMI with 0.1% FBS. Erlotinib (Apollo Scientific
Limited) was added at indicated concentrations, EGF
(Sigma) was added as indicated (100 ng/μl), and
KHS101 was added at 5 μM.
Transfections
Transfection experiments were performed using
polyethylenimine (PEI). Briefly, for a 12-well plate,
50 μl DMEM and PEI (10 mg/ml-stock) were added
in a ratio of 4:1 to the DNA. Tubes were vortexed and
incubated at room temperature for 15 min, and the
DNA mixture was added dropwise to the cells. Then,
5–16 h later, the transfection mix was removed and
replaced with indicated media.
MaMTH EGFR interactor screen
Genes were cloned into lentiviral prey back-
bones. After lentivirus harvest, target cells (stable
5xGAL4UAS-luciferase reporter-HEK293T cells)
were infected with prey viruses at a MOI of around
0.4. Cells were selected in puromycin (1.5 μg/ml)
for 2 days, cell counts were performed, and equal
amounts of cells were transfected with EGFR-WT,
EGFR-L858R, EGFR-ex19del, and EGFR-L858R/
T790M baits in triplicates. Then, 24 h after trans-
fection, cells were lysed and luciferase assays
performed. Each set of experiments contained a
defined set of negative prey controls (GABBR2,
PEX7, GABBR1, KCTD6, FABP5, and PEX19) in
three replicates as described in Ref. [13]. Negative
controlswere chosen as such that therewas a range of
controls showing high-background luciferase activity
292 Oncogenic EGFR Interaction Partners(cytosolic proteins) andmedium-background luciferase
activity (membrane-bound proteins). Negative controls
were averaged, and the fold change of luciferase
activity was calculated for each of the preys. Three
independent replicates of interaction assays were
performed, and statistical significance was assessed
by using one-way ANOVA.Cell viability assay
Cell viability assays using the Presto Blue
reagent were performed according to the manual
(ThermoFisher, Presto Blue Cell Viability Reagent).
Briefly, 10,000 cells of indicated stable cell lines
(H1975-shGFP control, H1975-shTACC3, and
H1975-TACC3-OE) were seeded into 96-well plates
in triplicates in a total volume of 90 μl. Then, 24 h after
seeding, the media were replaced with fresh media
containing indicated concentrations of erlotinib. Then,
48 h after treatment, 10 μl of Presto Blue reagent was
added to each well and incubated at 37 °C for 10 min,
and fluorescence was measured on a PerkinElmer
EnVision II plate reader with the excitation/emission
wavelengths set at 544/620 nm. Statistical analyses
were performed using one-way ANOVA.SRE-luciferase assays
HEK293T cells were seeded at 40,000 cells/well in a
24-well dish. The next day, TACC3 overexpression
constructs or lentiviral shTACC3 constructs were
transfected together with either SRE-luciferase or
Atg4-luciferase constructs. Then, 3 days after trans-
fection, cells were lysed in RIPA buffer, 10 μl was
transferred into 96-well plates, and 100 μl of BrigthGlo
(Promega) luciferase substrate was added. Lumines-
cence was measured on a PerkinElmer EnVision II
plate reader. Luciferase activity was measured in
triplicates and compared to empty vector control.
Statistical analyses were performed using one-way
ANOVA.Antibodies and Western blot analysis
Western blot analysis was performed using
standard protocols. Briefly, cells were lysed in
RIPA buffer containing phosphatase inhibitor
(PhosSTOP, Roche) and protease inhibitor
(EDTA-free tablets, Roche) on ice for 10 min, and
2x sample buffer was added, and samples were
immediately boiled at 95 °C for 5 min and pro-
ceeded for Western Blot analysis. Then, 5–10% of
the lysates were separated by 10% SDS-PAGE
gels and transferred to nitrocellulose membranes
(BioRad). Transferred samples were immunoblotted
with primary antibodies, followed by incubation with
horseradish peroxidase (HRP)-coupled secondaryantibodies, and detection was performed using
EZ-ECL enhanced luminescence detection kit (Biolog-
ical Industries). A list of antibodies used can be found in
Supplementary Table 4.
Co-immunoprecipitations
HEK293T cells were seeded at 300,000 cells/well in
a 6-well dish. The following day, cells were co-
transfected with plasmids encoding Flag-tagged
candidate EGFR interactors and GFP-tagged EGFR.
After 24-h transfection, cells were stimulated with EGF
(100 ng/ml) for 5 min, washed twice with ice-cold
phosphate-buffered saline (PBS), and lysed in 500 μl
NP40 lysis buffer [50 mM Hepes-NaOH (pH 8),
100 mM NaCl, 1 mM EGTA, 0.5% NP40, 2.5 mM
MgCl2, 1 mM DTT, and 10% glycerol] supplemented
with protease and phosphatase inhibitors (PhosSTOP
tablets from Roche; Complete EDTA-free protease
inhibitor tablets fromRoche). The total cell lysateswere
centrifuged at 20,800g for 30 min, and 20 μl superna-
tant was immediately frozen (= input samples).
Flag-tagged candidate proteins were immunoprecipi-
tated by incubating lysates with 25 μl anti-Flag M2
antibody-conjugated agarose (50% slurry) for 3–4 h at
4 °C. Beads were washed three times with lysis buffer,
and proteins were eluted by adding 2x sample buffer
(SB) plus β-mercaptoethanol. Proteins were resolved
on 10% SDS-PAGE. Levels of GFP-EGFR were
detected by immunoblotting using anti-GFPantibodies.
Fluorescence microscopy
EGFR-GFP and FLAG-tagged TACC3 were trans-
fected intoHeLa cells seededonglass slips. Cellswere
starved overnight and treated with EGF (100 ng/μl) for
indicated times, and 24 h after transfection, cells were
fixed in 4% paraformaldehyde and stained with
Hoechst33342, and fluorescence microscopy was
performed. Cells were examined using a Leica TCS
SPE confocal microscope (SPE3) withGFP and Texas
Red filters.
For Alexa-EGF555 endocytosis assays, cells were
transfected with indicated constructs and starved
overnight; Alexa-EGF555 was added (50 ng/μl) and
cells were kept on ice for 30 min before being released
into 37 °C incubator for indicated times. Cells were
then washed twice with ice-cold PBS, fixed in 4%PFA,
and stained with Hoechst33342, and fluorescence
microscopy was performed.GFP-Grb2 translocation assay
HeLa cells were seeded in 96-well plates (Perkin
Elmer, ViewPlate-96 Black, Optically Clear Bottom)
and were transfected (PEI-transfection) with 100 ng
GFP-Grb2 and 100 ng 19 FLAG-tagged interactors
24 h after seeding. The next day, cells were fixed with
293Oncogenic EGFR Interaction Partners4%paraformaldehydeandstainedwithHoechst33342,
and imaging was performed using the Perkin Elmer
Opera LX high-content screening confocal microscope
using a 40× objective.
EGFR predictions and bioinformatics analysis
Known and predicted interaction partners of EGFR
were downloaded from the Integrated Interactions
Database [33] version 2015-09. Protein domains
were retrieved from the UniProt database [34]
release-2015_08. Lung cancer prognostic signatures
and differential gene expression data were down-
loaded from the LCDIP database (D. Strumpf,
unpublished results), which includes prognostic sig-
natures from Ref. [35] and other sources.
Prognostic properties of TACC3 were evaluated
using http://kmplot.com (version 2015; data down-
loaded on March 6, 2016) [19]. Both adeno and
squamous cell lung cancer samples were used, and
biased samples were removed (n = 1926). Probe
218308_at, auto select best cutoff and censor at
threshold value was used. Obtained hazard ratios
and corresponding p-values were plotted. Resulting
KM plots for overall survival are included in Fig. 6a.
Cell surface biotinylation assay
Cells were starved overnight, treated with EGF
(100 ng/μl) for indicated times, and washed twice
with ice-cold PBS. Cells were incubated for 15 min on
ice with 0.5 mg/ml EZ Link™ Sulfo-NHS-SS-Biotin
(Pierce) and were washed twice with 100 mM glycine/
PBS to quench the reaction. Then, 500 μl lysis buffer
[50 mM Hepes-NaOH (pH 8), 100 mM NaCl, 1 mM
EGTA, 0.5% NP40, 2.5 mM MgCl2, 1 mM DTT, and
10% glycerol, supplemented with protease and phos-
phatase inhibitors] was added, and cells were kept on
ice for another 15 min. Cells were scraped into tubes
and spun down at 4 °C for 15 min. Then, 20 μL was
taken as input sample and frozen immediately. The rest
of the lysates were added to 25 μl washed magnetic
streptavidin-Dynabeads (ThermoFisher) and rotated at
4 °C for 3–4 h. Beads were washed three times with
lysis buffer. After the third wash, 40 μl 2x sample buffer
supplemented with β-mercaptoethanol was added to
the beads, boiled for 5 min, and frozen at −20 °C.
EGFR bands were quantified using ImageJ software
and normalized against transferrin receptor. Statistical
significance was assessed by one-way ANOVA.
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2016.12.006.Acknowledgments
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EGF, epidermal growth factor; EGFR, epidermal growth
factor receptor; ERK, extracellular signal-regulated kinase;
GFP, green fluorescent protein; Grb2, growth factor
receptor-bound protein 2; SH, Src homology; MAPK,
mitogen-activated protein kinase; TK, tyrosine kinase; TKI,
TK inhibitor; NSCLC, non-small cell lung cancer; MaMTH,
mammalian membrane two-hybrid; TACC, transforming
acidic coiled-coil protein; GO, gene ontology; Cub, C-
terminal half of ubiquitin; TF, transcription factor; Nub, N-
terminal half of ubiquitin; MOI, multiplicity of infection; EGFR-
WT, EGFR-wildtype; EGFR-ex19del, EGFR-exon19 dele-
tion; SRE, serum response element; KM, Kaplan–Meier;
FGFR, fibroblast growth factor receptor; DMEM, Dulbecco's
modified Eagle's medium; PEI, polyethylenimine; PBS,
phosphate-buffered saline.References
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